The Experimental Study On Rofecoxib Suppressing The Angiogenesis Of Gastric Carcinoma By Regulating The Expression Of Vascular Endothelial Growth Factor And Inducible Nitric Oxide Synthase

Objective: To study on cyclooxygenase-2 inhibitor rofecoxib suppressing the angiogenesis of gastric carcinoma model established in nude mice bearing human SGC-7901 cell by regulating the expression of vascular endothelial growth factor (VEGF) and inducible nitric oxide synthase (iNOS). Methods: To establish the models of human gastric carcinoma in nude mice by orthotopic transplantation, rofecoxib were taken by nude mice per day .Then the local tumor weight, inhibitary rates, the metastasis of liver and ascitic fluid formation were evaluated. EnVision immunohistochemical staining and RT-PCR were used to detect the expression of VEGF, iNOS at the level of protein and mRNA respectively. Results: Models of human gastric carcinoma in nude mice by orthotopic transplantation was made successful. The formation rate of transplanted tumour was 100%; Compared with the weight of orthotopic tumor in control group, tumor weight in rofecoxib group were significantly inhibited (p<0.05). The inhibitory rate of tumor was 41.2%. In addition, the incidences of liver metastasis and ascitic fluid formation were also decreased in the rofecoxib group. Expression of VEGF and iNOS in rofecoxib group were significantly lower than that of the control group by EnVision immunohistochemical and RT-PCR method (p<0.05). Conclusions: Rofecoxib can significantly inhibit the growth and metastasis of orthotopic transplantation gastric carcinoma of nude mice by downregulating the expression of VEGF, iNOS protein and mRNA which suppress the angiogenesis of gastric carcinoma.